Clinical trials: Extramembranous Glomerulopathy
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Primary Membranous Nephropathy
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial.
- Trial name
- NCT05696613
- Testing
- SNP-ACTH (1-39) Gel, Rituximab
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- Cerium Pharmaceuticals, Inc.
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants…
- Trial name
- NCT07029139
- Testing
- JMT601 Injection, Rituximab, Cyclosporin Capsules
- Volunteers
- 156 people
- Sponsor
- Shanghai JMT-Bio Inc.
Primary Membranous Nephropathy
A Phase I Study of YK012 in Primary Membranous Nephropathy
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).
- Trial name
- NCT07234474
- Testing
- YK012
- Volunteers
- 66 people
- Sponsor
- Excyte Biopharma Ltd
Lupus Membranous Nephropathy
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
- Trial name
- NCT03285711
- Testing
- Filgotinib, Lanraplenib
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Gilead Sciences
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Primary Membranous Nephropathy
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics（PD）and anti-drug antibodies（ADA） of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).
- Trial name
- NCT05862233
- Testing
- MIL62, Cyclosporine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Primary Membranous Nephropathy
Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
This is a randomized, open-label, cyclosporine-controlled, multicenter Phase III study. It aims to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of zuberitamab versus cyclosporine in patients with primary…
- Trial name
- NCT07830433
- Testing
- Zuberitamab 1000mg, Cyclosporine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Primary Membranous Nephropathy
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
- Trial name
- MAJESTY (NCT04629248)
- Testing
- Obinutuzumab, Tacrolimus, Methylprednisolone
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 142 people
- Sponsor
- Hoffmann-La Roche
Glomerulonephritis, Membranous
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
The main clinical study will be a randomized, double-blind, placebo-controlled, long term study involving a 100 week treatment period.
- Trial name
- NCT01762852
- Testing
- Belimumab 10 mg
- Where
- 30 sites in United States, Australia and 8 more
- Sponsor
- GlaxoSmithKline
Primary Membranous Nephropathy
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
- Trial name
- PrisMN (NCT07096843)
- Testing
- budoprutug
- Where
- 38 sites in United States, Argentina and 5 more
- Volunteers
- 45 people
- Sponsor
- Climb Bio, Inc.
Primary Membranous Nephropathy
Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy
The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.
- Trial name
- NCT05136456
- Testing
- SHR1459 Low Dose, SHR1459 High Dose
- Where
- 19 sites in China
- Volunteers
- 61 people
- Sponsor
- Reistone Biopharma Company Limited
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney.
- Trial name
- PROMINENT (NCT06962800)
- Testing
- Felzartamab, Tacrolimus, Standard of Care IST
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Biogen
Primary Membranous Nephropathy
A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy
This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group.
- Trial name
- NCT05398653
- Testing
- MIL62, Cyclosporine
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Primary Membranous Nephropathy
Study of YK012 in Primary Membranous Nephropathy
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).
- Trial name
- NCT06982729
- Testing
- YK012
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Excyte Biopharma Ltd
Primary Membranous Nephropathy
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
- Trial name
- AUTUMN (NCT07157787)
- Testing
- ALXN1920
- Where
- 40 sites in United States, Argentina and 8 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Membranous Nephropathy, Lupus Nephritis (LN)
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis.
- Trial name
- NCT07038382
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Henlius Biotech
Primary Membranous Nephropathy
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory Primary Membranous Nephropathy.The primary objectives are to assess the safety of FKC289 and to establish the…
- Trial name
- NCT07765537
- Testing
- FKC289 injection
- Where
- 8 sites in China
- Volunteers
- 55 people
- Sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Primary Membranous Nephropathy
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
- Trial name
- CLEAR-AbKD (NCT07571746)
- Testing
- Surovatamig
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Primary Membranous Nephropathy
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the…
- Trial name
- NCT05668403
- Testing
- B007
- Where
- 6 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd